-
Mashup Score: 11Does FDA Withdrawal of Cancer Drug Show Bigger Changes Needed? - 1 month(s) ago
The recent withdrawal a cancer drug that had been granted accelerated approval by the FDA may be illustrative of concerns raised by some critics.
Source: www.obroncology.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Doc Debates CEO as Calls to End MOC Intensify - 8 month(s) ago
Aaron Goodman, MD, recently debated the CEO of the American Board of Internal Medicine about whether Maintenance of Certification should continue.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Doc Debates CEO as Calls to End MOC Heat Up ABIM remains silent still. Hoping things blow over. Doesn't appear to be the case this time. https://t.co/ix001v67oU #OBRoncology via @OBRTweets
-
-
Mashup Score: 0Oncologists Wary of Fallout From Proposed Blood Biopsy Coverage Bill - 8 month(s) ago
Oncologists may soon face increased workloads if blood biopsy insurance coverage expands, as PCPs are likely to increasingly refer patients with unclear results.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Galleri reimbursement approval will make things messier .. Oncologists Wary of Proposed Bill’s Fallout https://t.co/vqtfSnjgM1 #OBRoncology via @OBRTweets
-
-
Mashup Score: 0Open-Label Placebo Pill Improves Cancer-Related Fatigue - 2 year(s) ago
Patients with advanced cancer who received an open-label placebo pill reported greater improvements in cancer-related fatigue than those who were put on a waitlist to get the placebo.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Open-Label Placebo Pill Improves Fatigue https://t.co/mSl0UIqJUF #OBRoncology via @OBRTweets
-
-
Mashup Score: 0
Dr. Gail Eckhardt, the American Society of Clinical Oncology (ASCO) 2022 Women Who Conquer Cancer Award recipient, discusses the importance of allowing mentees to pivot in their careers, the inherent bias when it comes to women in oncology leadership, and ways to maintain a work/life balance.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
ICYMI: A mentoring superstar! @utswcancer @UTSWHemeOnc @ASCO @ConquerCancerFd https://t.co/x86EPjbNDU #OBRoncology via @OBRTweets
-
-
Mashup Score: 0What’s Next for Immuno-Oncology? Jedd D. Wolchok Discusses - 2 year(s) ago
Robert Figlin, MD, and David Karnofsky Award recipient Jedd Wolchok, MD, PhD, discuss the future of immunotherapy, including new directions in combination therapy, how to think about side effects of adjuvant therapy, and the benefits of multidisciplinary collaboration.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
What’s Next for Immuno-Oncology? #asco22 w/ Karnofsky award recipient Jess Wolchok https://t.co/9GuaG3YpPn #OBRoncology
-
-
Mashup Score: 1
(BioPharma Dive) May 26, 2022 – Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive gene called KRAS.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Mirati Matches Amgen With Updated Data For KRAS-Blocking Cancer Drug https://t.co/GYa2fsEWxC #OBRoncology via @OBRTweets #ASCO22
-
-
Mashup Score: 2
(BMS) May 16, 2022 – Bristol Myers Squibb today announced the Phase 3 CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 ≥1% at final…
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Checkmate 901 showed that all-IO Nivo/Ipi (2 year duration of therapy) failed to improve OS over standard platinum-based chemo (4-6 cycles GC) in metastatic urothelial cancer with PDL1 >= 1%. Chemo remains a key part of SOC in this subset. https://t.co/pbSssKHOs4 #OBRoncology
-
-
Mashup Score: 0Positive Patient-Reported Outcomes Data Expand On The Efficacy Benefits Of Trastuzumab Deruxtecan And Pembrolizumab - 2 year(s) ago
(ESMO Breast Cancer 2022) May 3, 2022 – Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Positive Patient-Reported Outcomes Data Expand On The Efficacy Benefits Of Trastuzumab Deruxtecan And Pembrolizumab https://t.co/I8lzMjb5Ij #OBRoncology via @OBRTweets
-
-
Mashup Score: 0
Neil O’Brien, PhD, of UCLA, discusses pre-clinical results showing that tucatinib, a novel HER2 inhibitor, shows much higher selectivity than other HER2 inhibitors, and tucatinib and trastuzumab together showed strong inhibition of HER2 signaling in cancer cells.
Source: www.obroncology.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Tucatinib Effectively Targets HER2+ Cancers https://t.co/QK4gs6XjOj #OBRoncology via @OBRTweets
-
Thanks for the chance to contribute to this excellent piece on @US_FDA Accelerated Approval and Withdrawal via @OBRTweets | FDA Cancer Drug Withdrawal Illustrates Concerns https://t.co/KGzGI6fK68 #OBRoncology